Q BioMed Inc. logo

Q BioMed Inc. (QBIO)

Market Open
15 Dec, 14:31
OTCQB OTCQB
OTCQB OTCQB Primary
$
0. 00
0
0%
$
29.02K Market Cap
- P/E Ratio
0% Div Yield
20,000 Volume
0 Eps
$ 0
Previous Close
Day Range
0 0
Year Range
0 0
Want to track QBIO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

QBIO trading today higher at $0, an increase of 0% from yesterday's close, completing a monthly increase of 0% or $0. Over the past 12 months, QBIO stock gained 0%.
QBIO is not paying dividends to its shareholders.
The last earnings report, released on Oct 29, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Q BioMed Inc. has completed 1 stock splits, with the recent split occurring on Aug 07, 2015.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTCQB (USD).

QBIO Chart

No Data

Similar

LEAT
Leatt Corporation
$ 9.4
+0.21%
MGROF
MustGrow Biologics Corp.
$ 0.41
+3.54%
TELIF
Telescope Innovations Corp.
$ 0.23
-1.72%
CLCS
Cell Source Inc.
$ 0.46
+24.64%
NBIO
Nascent Biotech Inc.
$ 0
-40%

Q BioMed Inc. (QBIO) FAQ

What is the stock price today?

The current price is $0.00.

On which exchange is it traded?

Q BioMed Inc. is listed on OTCQB.

What is its stock symbol?

The ticker symbol is QBIO.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 29.02K.

Has Q BioMed Inc. ever had a stock split?

Q BioMed Inc. had 1 splits and the recent split was on Aug 07, 2015.

Q BioMed Inc. Profile

Biotechnology Industry
Healthcare Sector
Mr. Denis D. Corin CEO
OTCQB Exchange
US74736N1054 ISIN
US Country
- Employees
- Last Dividend
7 Aug 2015 Last Split
- IPO Date

Overview

Q BioMed Inc. is a biomedical acceleration and development company that specializes in licensing, acquiring, and providing resources to life sciences and healthcare entities. Initially named ISMO Tech Solutions, Inc., the company underwent a rebranding to Q BioMed Inc. in July 2015. Founded in 2013 and headquartered in New York, New York, the organization aims to facilitate the advancement of therapeutic and diagnostic products from development stages through to commercialization. Q BioMed Inc. has forged a strategic partnership with Mannin Research Inc. to pioneer the development of therapeutic drugs aimed at addressing a diverse array of medical conditions, including acute respiratory distress syndrome, glaucoma, kidney diseases, and more.

Products and Services

Q BioMed Inc. offers a comprehensive portfolio of products and services aimed at addressing critical medical needs. These include:

  • Strontium Chloride Sr-89 and Metastron: A radiopharmaceutical therapeutic duo used in the treatment of metastatic bone cancer pain, providing relief to patients suffering from this severe condition.
  • Man-01: A cutting-edge treatment under development for primary open angle glaucoma, showcasing Q BioMed Inc.'s commitment to combating major eye diseases with innovative solutions.
  • QBM-001: Tailored for the rare pediatric non-verbal autism spectrum disorder, this treatment represents the company's focus on addressing underserved medical areas, especially within pediatric care.
  • Uttroside-B: A novel chemotherapeutic agent for liver cancer, highlighting Q BioMed Inc.'s contribution to the fight against cancer with promising new treatments.

Contact Information

Address: 366 Madison Avenue, New York, NY, United States, 10017
Phone: 212 588 0022
Download app banner
Affiliate Program About Terms Privacy Help Contact Us
2025 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark